References
  1. Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected.Interim guidance V 1.2. 2020.
  2. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. Allergy 2020.
  3. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 2020;26(4):502-505.
  4. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020.
  5. Monteagudo LA, Boothby A, Gertner E. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.ACR Open Rheumatol 2020.
  6. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020:105954.
  7. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020.
  8. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.JAMA 2020.
  9. Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther2020.
  10. Health TMo. Turkish Ministry ofHealth COVID-19 Guideline 14.04.2020. 2020.
  11. Direzione Generale Cura della Persona SeW. Indirizzi terapeutici della Regione E-R per il trattamento della infezione da SARS-CoV2 (COVID-19). 2020.
  12. Garvey LH, Ebo DG, Mertes PM, Dewachter P, Garcez T, Kopac P, et al. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. Allergy2019;74(10):1872-1884.
  13. Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy 2019.
  14. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58(9):854-863.
  15. Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy2019;74(1):14-27.
  16. Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy2016;71(2):149-161.
  17. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper.Allergy 2013;68(6):702-712.
  18. Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper.Allergy 2016;71(8):1103-1134.
  19. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy2010;65(11):1357-1366.
  20. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions – an EAACI position paper of the Drug Allergy Interest Group.Allergy 2013;68(7):844-852.
  21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
  22. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020 Apr 29.
  23. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol2020.
  24. Hunt M, Koziatek C. A Case of COVID-19 Pneumonia in a Young Male with Full Body Rash as a Presenting Symptom. Clin Pract Cases Emerg Med 2020.
  25. Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020.
  26. Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Pediatr Dermatol 2020.
  27. Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones OM, Fernandez-Nieto D. Reply to ”COVID-19 can present with a rash and be mistaken for Dengue”: Petechial rash in a patient with COVID-19 infection. J Am Acad Dermatol 2020.
  28. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on ”Cutaneous manifestations in COVID-19: a first perspective ” by Recalcati S. J Eur Acad Dermatol Venereol2020.
  29. Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, Boggio F, et al. Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy. Acta Derm Venereol 2020.
  30. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020;82(5):e177.
  31. Manalo IF, Smith MK, Cheeley J, Jacobs R. A Dermatologic Manifestation of COVID-19: Transient Livedo Reticularis. J Am Acad Dermatol2020.
  32. Kolivras A, Dehavay F, D. D, Feoli F, Meiers I, Milone L, et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathological findings. JAAD Case Reports 2020.
  33. Mazzotta F, Troccoli T, Bonifazi E. A new vasculitis at the time of COVID-19. European Journal Of Pediatric Dermatology - pd online2020.
  34. Fernandez-Ni”eto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A, et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol. 2020 Apr 24. pii: S0190-9622(20)30709-X.
  35. Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi2020;41(0):E006.
  36. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.Transl Res 2020.
  37. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents2020:105955.
  38. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19(3):149-150.
  39. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect 2020.
  40. Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Curr Med Chem 2020.
  41. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40.
  42. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ2014;348:g2545.
  43. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther2007;25(10):1153-1162.
  44. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19.N Engl J Med 2020.
  45. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370(9581):49-58.
  46. Zuo W, Wen LP, Li J, Mei D, Fu Q, Zhang B. Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report.Medicine (Baltimore) 2019;98(19):e15553.
  47. Gonzalez-Ramos J, Lamas C, Bellon T, Ruiz-Bravo E, Ramirez E, Lerma V, et al. Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing’s disease. Indian J Dermatol Venereol Leprol 2019.
  48. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of Remdesivir for Patients with Severe COVID-19.N Engl J Med 2020.
  49. Brillanti S, Mazzella G, Roda E. Ribavirin for chronic hepatitis C: and the mystery goes on. Dig Liver Dis 2011;43(6):425-430.
  50. Lorcy S, Gaudy-Marqueste C, Botta D, Portal I, Quiles N, Oulies V, et al. [Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study]. Ann Dermatol Venereol 2016;143(5):336-346.
  51. Patrk I, Morovic M, Markulin A, Patrk J. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin. Dermatology 2014;228(1):42-46.
  52. Brok J, Gluud LL, Gluud C. Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C - an updated Cochrane review. Aliment Pharmacol Ther 2010;32(7):840-850.
  53. Barreira P, Cadinha S, Malheiro D, da Silva JP. Delayed hypersensitivity to ribavirin confirmed by provocation test. J Investig Allergol Clin Immunol 2014;24(6):441-442.
  54. Shindo M, Terai I. Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-alpha2a.Case Rep Dermatol 2013;5(3):379-381.
  55. Ladd AM, Martel-Laferriere V, Dieterich D. Successful desensitization to ribavirin in a patient with chronic hepatitis C. J Clin Gastroenterol 2012;46(8):716-717.
  56. Toker O, Tal Y, Daher S, Shalit M. Ribavirin Desensitization in Chronic Hepatitis C. Isr Med Assoc J 2015;17(9):583-584.
  57. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir).Ann Pharmacother 2002;36(7-8):1193-1203.
  58. Ghosn J, Duvivier C, Tubiana R, Katlama C, Caumes E. Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir. Clin Infect Dis 2005;41(9):1360-1361.
  59. Echeverria P, Negredo E, Carosi G, Galvez J, Gomez JL, Ocampo A, et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naive patients: a 48-week, multicentre, randomized study (Lake Study). Antiviral Res 2010;85(2):403-408.
  60. Sun L, Deng X, Chen X, Huang J, Huang S, Li Y, et al. Incidence of adverse drug reactions in COVID-10 patients in China: An active monitoring study by hospital pharmacovigilance system. Clin Pharmacol Ther  2020 Apr 23.
  61. Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007;46(1):24-31.
  62. Buijs BS, van den Berk GE, Boateng CP, Hoepelman AI, van Maarseveen EM, Arends JE. Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS2015;29(7):785-791.
  63. Marcos Bravo MC, Ocampo Hermida A, Martinez Vilela J, Perez Rodriguez MT, Gavilan Montenegro MJ, Arenas Villarroel LJ, et al. Hypersensitivity reaction to darunavir and desensitization protocol.J Investig Allergol Clin Immunol 2009;19(3):250-251.
  64. Lorber M, Haddad S. Hypersensitivity and desensitization to darunavir in a case of HIV infection with triple-class drug resistance: case description and review of the literature. J Int Assoc Provid AIDS Care 2013;12(6):378-379.
  65. Hirschfeld G, Weber L, Renkl A, Scharffetter-Kochanek K, Weiss JM. Anaphylaxis after Oseltamivir (Tamiflu) therapy in a patient with sensitization to star anise and celery-carrot-mugwort-spice syndrome.Allergy 2008;63(2):243-244.
  66. Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo) 2019;72(10):759-768.
  67. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.
  68. Araujo L, Demoly P. Macrolides allergy. Curr Pharm Des2008;14(27):2840-2862.
  69. Mori F, Pecorari L, Pantano S, Rossi ME, Pucci N, De Martino M, et al. Azithromycin anaphylaxis in children. Int J Immunopathol Pharmacol 2014;27(1):121-126.
  70. Barni S, Butti D, Mori F, Pucci N, Rossi ME, Cianferoni A, et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. J Investig Allergol Clin Immunol 2015;25(2):128-132.
  71. Schissel DJ, Singer D, David-Bajar K. Azithromycin eruption in infectious mononucleosis: a proposed mechanism of interaction.Cutis 2000;65(3):163-166.
  72. Milkovic-Kraus S, Macan J, Kanceljak-Macan B. Occupational allergic contact dermatitis from azithromycin in pharmaceutical workers: a case series. Contact Dermatitis 2007;56(2):99-102.
  73. Mendes-Bastos P, Bras S, Amaro C, Cardoso J. Non-occupational allergic contact dermatitis caused by azithromycin in an eye solution. J Dtsch Dermatol Ges 2014;12(8):729-730.
  74. An I, Demir V, Akdeniz S. Fixed drug eruption probably induced by azithromycin. Australas J Dermatol 2017;58(4):e253-e254.
  75. Campanon-Toro MV, Sierra O, Moreno E, Sobrino-Garcia M, Gracia-Bara MT, Davila I. Acute generalized exanthematous pustulosis (AGEP) induced by azithromycin. Contact Dermatitis 2017;76(6):363-364.
  76. Sriratanaviriyakul N, Nguyen LP, Henderson MC, Albertson TE. Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report. J Med Case Rep 2014;8:332.
  77. Aihara Y, Ito S, Kobayashi Y, Aihara M. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Allergy 2004;59(1):118.
  78. Xu L, Zhu Y, Yu J, Deng M, Zhu X. Nursing care of a boy seriously infected with Steven-Johnson syndrome after treatment with azithromycin: A case report and literature review. Medicine (Baltimore) 2018;97(1):e9112.
  79. Odemis E, Kalyoncu M, Okten A, Yildiz K. Azithromycin-induced leukocytoclastic vasculitis. J Rheumatol 2003;30(10):2292.
  80. Pursnani A, Yee H, Slater W, Sarswat N. Hypersensitivity myocarditis associated with azithromycin exposure. Ann Intern Med2009;150(3):225-226.
  81. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003;112(3):629-630.
  82. Won HK, Yang MS, Song WJ, Kim SH, Park HW, Chang YS, et al. Determination of nonirritating concentrations of antibiotics for intradermal skin tests in Korean adults. J Allergy Clin Immunol Pract 2017;5(1):192-194 e192.
  83. Seitz CS, Brocker EB, Trautmann A. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. Allergol Immunopathol (Madr)2011;39(4):193-199.
  84. Unal D, Demir S, Gelincik A, Olgac M, Coskun R, Colakoglu B, et al. Diagnostic value of oral challenge testing in the diagnosis of macrolide hypersensitivity. J Allergy Clin Immunol Pract 2018;6:521-7.
  85. Staso P, Leonov A. Drug desensitization in 17-year-old male with Mast Cell Activation Syndrome, pneumonia, and antibiotic hypersensitivities. AME Case Rep 2017;1:7.
  86. Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J 2020.
  87. Soria A, Barbaud A, Assier H, Avenel-Audran M, Tetart F, Raison-Peyron N, et al. Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests. Dermatology 2015;231(4):353-359.
  88. Matsuda T, Ly NTM, Kambe N, Nguyen CTH, Ueda-Hayakawa I, Son Y, et al. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.J Dermatol 2018;45(3):344-348.
  89. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).Br J Dermatol 2007;157(5):989-996.
  90. Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G. Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol2008;27(4):537-539.
  91. Schmutz JL, Barbaud A, Trechot P. [Hydroxychloroquine and DRESS].Ann Dermatol Venereol 2008;135(12):903.
  92. Girijala RL, Siddiqi I, Kwak Y, Wright D, Patel DB, Goldberg LH. Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV Reactivation. J Drugs Dermatol 2019;18(2):207-209.
  93. Perez-Ezquerra PR, de Barrio Fernandez M, de Castro Martinez FJ, Ruiz Hornillos FJ, Prieto Garcia A. Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient. Allergol Immunopathol (Madr)2006;34(4):174-175.
  94. Phillips-Howard PA, Warwick Buckler J. Idiosyncratic reaction resembling toxic epidermal necrolysis caused by chloroquine and maloprim. Br Med J (Clin Res Ed) 1988;296(6636):1605.
  95. Kanny G, Renaudin JM, Lecompte T, Moneret-Vautrin DA. Chloroquine hypersensitivity syndrome. Eur J Intern Med 2002;13(1):75-76.
  96. Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 2001;26(5):457-458.
  97. Cameron MC, Word AP, Dominguez A. Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatol Online J2014;20(11).
  98. Lisi P, Assalve D, Hansel K. Phototoxic and photoallergic dermatitis caused by hydroxychloroquine.Contact Dermatitis 2004;50(4):255-256.
  99. Meier H, Elsner P, Wuthrich B. [Occupationally-induced contact dermatitis and bronchial asthma in a unusual delayed reaction to hydroxychloroquine]. Hautarzt1999;50(9):665-669.
  100. Charfi O, Kastalli S, Sahnoun R, Lakhoua G. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing. Indian J Pharmacol 2015;47(6):693-694.
  101. Mates M, Zevin S, Breuer GS, Navon P, Nesher G. Desensitization to hydroxychloroquine–experience of 4 patients. J Rheumatol2006;33(4):814-816.
  102. Caramaschi P, Barbazza R, Tinazzi I, Biasi D. Desensitization to hydroxychloroquine: 4 cases. J Rheumatol 2011;38(10):2267; author reply 2267.
  103. Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus 2018;27(5):703-707.
  104. Barailler H, Milpied B, Chauvel A, Claraz P, Taieb A, Seneschal J, et al. Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization.J Allergy Clin Immunol Pract 2019;7(1):307-308.
  105. Rowane M, Schend J, Patel J, Hostoffer R, Jr. Rapid desensitization of hydroxychloroquine.Ann Allergy Asthma Immunol 2020;124(1):97-98.
  106. Donado CD, Diez EM. Successful desensitization for hydroxychloroquine anaphylaxis. J Rheumatol 2010;37(9):1975-1976. X
  107. Perez-Sanchez N, Esponda-Juarez K, Cimarra Alvarez M, Aleo Lujan E, Toledano Martinez E, Fernandez-Rivas MM. Short desensitization in an adolescent with hydroxychloroquine anaphylaxis. Pediatr Allergy Immunol 2014;25(8):819-821.
  108. Rothan HA,  Stone S, Natekar J,  Kumari P,  Arora K,   Kumar M. The FDA- approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.  https://www.biorxiv.org/content/10.1101/2020.04.14.041228v1.
  109. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J, Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005;326(4):905-908.
  110. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11(1):222.
  111. Vazquez-Lopez F, Manjon-Haces JA, Perez-Alvarez R, Perez-Oliva N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment.Br J Dermatol 2004;150(5):1046-1047; author reply 1047.
  112. Kerl K, Negro F, Lubbe J. Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. Br J Dermatol 2003;149(3):656.
  113. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol2014;13(7):657-665.
  114. Milkiewicz P, Yim C, Pache I, Heathcote J. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon.Can J Gastroenterol 2005;19(11):677-678.
  115. Cottoni F, Bolognini S, Deplano A, Garrucciu G, Manzoni NE, Careddu GF, et al. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon? Acta Derm Venereol 2004;84(2):120-123.
  116. Poreaux C, Bronowicki JP, Debouverie M, Schmutz JL, Waton J, Barbaud A. Clinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization. Clin Exp Allergy2014;44(5):756-764.
  117. Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J Drugs Dermatol 2003;2(5):570-573.
  118. Conroy M, Sewell L, Miller OF, Ferringer T. Interferon-beta injection site reaction: review of the histology and report of a lupus-like pattern. J Am Acad Dermatol 2008;59(2 Suppl 1):S48-49.
  119. Brown DL, Login IS, Borish L, Powers PL. An urticarial IgE-mediated reaction to interferon beta-1b. Neurology2001;56(10):1416-1417.
  120. Kalpaklioglu FA, Baccioglu Kavut A, Erdemoglu AK. Desensitization in interferon-beta1a allergy: a case report. Int Arch Allergy Immunol 2009;149(2):178-180.
  121. Cortellini G, Amadori A, Comandini T, Corvetta A. Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests. Eur Ann Allergy Clin Immunol 2013;45(5):181-182.
  122. Sakatani A, Doi Y, Matsuda T, Sasai Y, Nishida N, Sakamoto M, et al. Protracted anaphylaxis developed after peginterferon alpha-2a administration for chronic hepatitis C. World J Gastroenterol2015;21(9):2826-2829.
  123. Meller S, Erhardt A, Auci A, Neumann NJ, Homey B. Drug-induced exanthema caused by pegylated interferon-alpha 2b. Hautarzt2003;54(10):992-993.
  124. Taghavi SA, Eshraghian A. Successful interferon desensitization in a patient with chronic hepatitis C infection. World J Gastroenterol2009;15(33):4196-4198.
  125. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res2020;178:104787.
  126. Ngwasiri CA, Abanda MH, Aminde LN. Ivermectin-induced fixed drug eruption in an elderly Cameroonian: a case report. J Med Case Rep 2018;12(1):254.
  127. Kerneuzet I, Blind E, Darrieux L, Moreau S, Safa G. Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. JAAD Case Rep 2018;4(6):524-527.
  128. Aroke D, Tchouakam DN, Awungia AT, Mapoh SY, Ngassa SN, Kadia BM. Ivermectin induced Steven-Johnsons syndrome: case report. BMC Res Notes 2017;10(1):179.
  129. Seegobin K, Bueno E, Maharaj S, Ashby T, Brown M, Jones L. Toxic epidermal necrolysis after ivermectin. Am J Emerg Med2018;36(5):887-889.
  130. Kelleni MT. Nitazoxanide/Azithromycin Combination for COVID-19: A Suggested New Protocol for COVID-19 Early Management. Pharmacol Res. 2020 Apr 30;104874.
  131. Regnier Galvao V, Castells MC. Hypersensitivity to biological agents- Updated diagnosis, management and treatment. J Allegy Clin Immunol Pract. 2015;3:174-185.
  132. Nakamura M, Tokura Y. Tocilizumab-induced erythroderma. Eur J Dermatol 2009;19(3):273-274.
  133. Yoshiki R, Nakamura M, Tokura Y. Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol2010;24(4):495-496.
  134. Soyer O, Demir S, Bilginer Y, Batu ED, Sonmez HE, Arici ZS, et al. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr Allergy Immunol 2019;30(8):833-840.
  135. Koc R, Sonmez HE, Cakan M, Karadag SG, Tanatar A, Cakmak F, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years’ experience of a tertiary pediatric rheumatology center. Rheumatol Int 2020;40(5):771-776.
  136. Rocchi V, Puxeddu I, Cataldo G, Del Corso I, Tavoni A, Bazzichi L, et al. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford) 2014;53(8):1527-1529.
  137. Tetu P, Hamelin A, Moguelet P, Barbaud A, Soria A. Management of hypersensitivity reactions to Tocilizumab. Clin Exp Allergy2018;48(6):749-752.
  138. Cortellini G, Mascella F, Simoncelli M, Lippolis D, Focherini MC, Cortellini F, et al. Effective Desensitization to Tocilizumab in Delayed Hypersensitivity Reaction. Pharmacology2018;102(1-2):114-116.
  139. Ben Said B, Gerfaud-Valentin M, Seve P. Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis. J Allergy Clin Immunol Pract 2018;6(3):1048-1049.
  140. Zuelgaray E, Domont F, Peiffer-Smadja N, Saadoun D, Cacoub P. Tocilizumab-Induced Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in Adult-Onset Still Disease. Ann Intern Med2017;167(2):141-142.
  141. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387(10031):1921-1927.
  142. Izquierdo JH, Bonilla-Abadia F, Ochoa CD, Agualimpia A, Tobon GJ, Canas CA. Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient. Case Rep Rheumatol 2012;2012:517424.
  143. Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, et al. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Mod Rheumatol 2019;29(2):324-327.
  144. den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65(6):760-762.
  145. Kaiser C, Knight A, Nordström D, Petterson T, Fransson J, Robertsson EF. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int (2012) 32:295–299. DOI 10.1007/s00296-011-2096-3.
  146. Soyyigit S, Kendirlinan R, Aydin O, Celik GE. Successful desensitization with anakinra in a case with immediate hypersensitivity reaction. Ann Allergy Asthma Immunol2014;113(3):325-326.
  147. Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother2009;43(5):967-972.
  148. Yılmaz I, Turk M, Nazik Bahcecioglu S. Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction. Eur Ann Allergy Clin Immunol 2018;50(2):94-96.
  149. Emmi G, Silvestri E, Cantarini L, Lopalco G, Cecchi L, Chiarini F, et al. Rapid desensitization to anakinra-related delayed reaction: Need for a standardized protocol. J Dermatol 2017;44(8):981-982.
  150. Bendele A, Colloton M, Vrkljan M, Morris J, Sabados K. Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications. J Lab Clin Med 1995;125(4):493-500.
  151. Lu CC, Chen MY, Chang YL. Potential therapeutic agents against COVID-19: What we know so far? J Chin Med Assoc. 2020 Apr 1;10.1097/JCMA.0000000000000318.
  152. Wells AF. Parrino J, Mangan EK, Paccaly A, Lin Y,. Xu C, et al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol Ther (2019) 6:339–352.
  153. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol2016;12(5):259-268.
  154. Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020 Apr 3:S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0.
  155. Stebbing J, Phelan A,  Griffin I,  Tucker C,  Oechsle O,  Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr; 20(4): 400–402.
  156. Fournier JB, Cummings F, Cannella J. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib. Dermatol Online J. 2014 Oct 15;20(10). pii: 13030/qt2jg3q02x
  157. Koumaki D, Koumaki V, Lagoudaki E, Bertsias G. Palmoplantar pustulosis-like eruption induced by baricitinib for treatment of rheumatoid athritis. Eur J Case rep Intern Med 2019; 19: 7(1):001383.
  158. Doohan BJ, Cranwell WC, Varigos GA, De Cruz R. An urticarial drug eruption caused by tofacitinib for alopecia universalis. Dermatologic Therapy. 2019;32:e12933.
  159. Shibata T, Muto J, Hirano Y, Hiroyuki T, Yanagishita T, Ohshima Y, et al. Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis. Ohshima,JAAD Case Reports 2019;5:518-21.
  160. de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Thiel V, Narayanan K, Makino S, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. Journal of General Virology (2011), 92, 2542–2548. DOI 10.1099/vir.0.034983-0.
  161. Volcheck GW, Van Dellen RG. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann Allergy Asthma Immunol 1998;80(2):159-163.
  162. Kang SY, Sohn KH, Lee JO, Kim SH, Cho SH, Chang YS. Intravenous tacrolimus and cyclosporine induced anaphylaxis: what is next?Asia Pac Allergy 2015;5(3):181-186.
  163. Ebo DG, Piel GC, Conraads V, Stevens WJ. IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine. Ann Allergy Asthma Immunol 2001;87(3):243-245.
  164. Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, et al. The Greek study in the Effects of Colchicine in Covid-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol J 2020 Apr 3;S1109-9666(20)30061-0.  doi: 10.1016/j.hjc.2020.03.002.
  165. Mochida K, Teramae H, Hamada T. Fixed drug eruption due to colchicine. Dermatology 1996;192:61.
  166. Levinger U, Monselise A. Reporting a desensitization protocol for colchicine treatment. Clin Exp Rheumatol 2001;19(5 Suppl 24):S79.
  167. Barbaud A, Trechot P, Reichert-Penetrat S, Commun N, Schmutz JL. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis. 2001 Nov;45(5):265-8.
  168. Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 2020;24(7):4040-4047.
  169. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, et al. Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 2018;17(6):519-529.
  170. Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep 2019;4(11):1568-1576.
  171. Lo R, Alexander S, Moss J, Siddiqi A, Liu A. Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome. J Allergy Clin Immunol Pract 2019;7(7):2409-2410.
  172. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet2020;395(10223):473-475.
  173. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther 2020;5(1):18.
  174. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect 2020;9(1):687-690.
  175. Ventura MT, Calogiuri GF, Muratore L, Di Leo E, Buquicchio R, Ferrannini A, et al. Cross-reactivity in cell-mediated and IgE-mediated hypersensitivity to glucocorticoids. Curr Pharm Des 2006;12(26):3383-3391.
  176. Baeck M, Marot L, Nicolas JF, Pilette C, Tennstedt D, Goossens A. Allergic hypersensitivity to topical and systemic corticosteroids: a review. Allergy 2009;64(7):978-994.
  177. Baker A, Empson M, The R, Fitzharris P. Skin testing for immediate hypersensitivity to corticosteroids: a case series and literature review. Clin Exp Allergy 2015;45(3):669-676.
  178. Patel A, Bahna SL. Immediate hypersensitivity reactions to corticosteroids. Ann Allergy Asthma Immunol 2015;115(3):178-182 e173.
  179. Aranda A, Mayorga C, Ariza A, Dona I, Blanca-Lopez N, Canto G, et al. IgE-mediated hypersensitivity reactions to methylprednisolone.Allergy 2010;65(11):1376-1380.
  180. Venturini M, Lobera T, del Pozo MD, Gonzalez I, Blasco A. Immediate hypersensitivity to corticosteroids. J Investig Allergol Clin Immunol 2006;16(1):51-56.
  181. Rachid R, Leslie D, Schneider L, Twarog F. Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. J Allergy Clin Immunol2011;127(2):524-528.
  182. Li PH, Wagner A, Thomas I, Watts TJ, Rutkowski R, Rutkowski K. Steroid Allergy: Clinical Features and the Importance of Excipient Testing in a Diagnostic Algorithm. J Allergy Clin Immunol Pract2018;6(5):1655-1661.
  183. Angel-Pereira D, Berges-Gimeno MP, Madrigal-Burgaleta R, Urena-Tavera MA, Zamora-Verduga M, Alvarez-Cuesta E. Successful rapid desensitization to methylprednisolone sodium hemisuccinate: a case report. J Allergy Clin Immunol Pract 2014;2(3):346-348.
  184. Guvenir H, Misirlioglu ED, Aydin F, Ece D, Cakar N, Kocabas CN. Successful methylprednisolone desensitization in a pediatric patient. Pediatr Allergy Immunol2017;28(3):305-306.
  185. Barbaud A, Waton J. Systemic Allergy to Corticosteroids: Clinical Features and Cross Reactivity. Curr Pharm Des. 2016;22(45):6825-6831.
  186. Padial A, Posadas S, Alvarez J, Torres MJ, Alvarez JA, Mayorga C, et al. Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism.Allergy 2005;60(5):665-670.
  187. Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.Thromb Haemost 2020.
  188. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy2006;61(12):1432-1440.
  189. Trautmann A, Seitz CS. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. Immunol Allergy Clin North Am2009;29(3):469-480.
  190. Bank I, Libourel EJ, Middeldorp S, Van Der Meer J, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost 2003;1(4):859-861.
  191. Tan E, Thompson G, Ekstrom C, Lucas M. Non-immediate heparin and heparinoid cutaneous allergic reactions: a role for fondaparinux. Intern Med J2018;48(1):73-77.
  192. Kim KH, Lynfield Y. Enoxaparin-induced generalized exanthem. Cutis2003;72(1):57-60.
  193. Seitz CS, Brocker EB, Trautmann A. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. Dermatol Online J2008;14(9):4.
  194. Rodriguez-Fernandez A, Sanchez-Dominguez M, Torrado-Espanol I, Noguerado-Mellado B, Rojas-Perez-Ezquerra P. Clinical Patterns of Heparin Allergy: Cross-reactivity Between Low-Molecular-Weight Heparins and Unfractionated Heparins. J Investig Allergol Clin Immunol 2019;29(2):132-134.
  195. Ronceray S, Dinulescu M, Le Gall F, Polard E, Dupuy A, Adamski H. Enoxaparin-Induced DRESS Syndrome.Case Rep Dermatol 2012;4(3):233-237.
  196. Bidaki R, Saeidi SA, Zarch MB. Delirious State and Agitation Following Heparin Induced Stevens-Johnson Syndrome. J Clin Diagn Res 2017;11(5):VL01.
  197. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71(2):247-251.
  198. Greinacher A. Heparin-Induced Thrombocytopenia. N Engl J Med 2015;373(19):1883-1884.
  199. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.Blood 2005;106(8):2710-2715.
  200. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 2004;34(12):1916-1918.
  201. Anders D, Trautmann A. Allergic anaphylaxis due to subcutaneously injected heparin. Allergy Asthma Clin Immunol 2013;9(1):1.
  202. Cesana P, Scherer K, Bircher AJ. Immediate Type Hypersensitivity to Heparins: Two Case Reports and a Review of the Literature. Int Arch Allergy Immunol2016;171(3-4):285-289.
  203. Leguisamo S, Prados Castano M, Pinero Saavedra M, Cimbollek S. Recurrent Anaphylaxis Due to Enoxaparin. J Investig Allergol Clin Immunol2015;25(4):297-299.
  204. Caballero MR, Fernandez-Benitez M. Allergy to heparin: a new in vitro diagnostic technique. Allergol Immunopathol (Madr)2003;31(6):324-328.
  205. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med2008;358(23):2457-2467.
  206. Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet2012;380(9856):1867-1879.
  207. Parekh K, Burkhart HM, Hatab A, Ross A, Muller BA. Heparin allergy: successful desensitization for cardiopulmonary bypass. J Thorac Cardiovasc Surg2005;130(5):1455-1456.
  208. Patriarca G, Rossi M, Schiavino D, Schinco G, Fais G, Varano C, et al. Rush desensitization in heparin hypersensitivity: a case report. Allergy 1994;49(4):292-294.
  209. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol2011;72(4):634-646.
  210. Tonew E, Indulen MK, Dzeguze DR. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol 1982;26(3):125-129.
  211. Fata-Hartley CL, Palmenberg AC. Dipyridamole reversibly inhibits mengovirus RNA replication. J Virol 2005;79(17):11062-11070.
  212. Liu X, Li Z, Liu S, Sun J, Chen Z, Jiang M, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B 2020.
  213. Salava A, Alanko K, Hyry H. Dipyridamole-induced eczematous drug eruption with positive patch test reaction. Contact Dermatitis 2012;67(2):103-104.
  214. Angelides S, Van der Wall H, Freedman SB. Acute reaction to dipyridamole during myocardial scintigraphy. N Engl J Med 1999;340(5):394.
  215. Weinmann P, Moretti JL, Leynadier F. Anaphylaxis-like reaction induced by dipyridamole during myocardial scintigraphy. Am J Med 1994;97(5):488.
  216. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy 2019;74(8):1457-1471.
  217. Trautmann A, Benoit S, Goebeler M, Stoevesandt J. !Treating through! Decision and follow-up in antibiotic therapy-associated exanthemas. J Allergy Clin Immunol Pract 2017: 5(6):1650-1656.